Lam A - Search Results

1

Systematic literature review of evidence in amyloid light-chain amyloidosis.

Lee C, Lam A, Kangappaden T, Olver P, Kane S, Tran D, Ammann E. Lee C, et al. Among authors: lam a. J Comp Eff Res. 2022 Apr;11(6):451-472. doi: 10.2217/cer-2021-0261. Epub 2022 Feb 21. J Comp Eff Res. 2022. PMID: 35188424 Free article. Review.

2

Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.

Durie BGM, Kumar SK, Usmani SZ, Nonyane BAS, Ammann EM, Lam A, Kobos R, Maiese EM, Facon T. Durie BGM, et al. Among authors: lam a. Am J Hematol. 2020 Dec;95(12):1486-1494. doi: 10.1002/ajh.25963. Epub 2020 Sep 5. Am J Hematol. 2020. PMID: 32804408 Free PMC article. Clinical Trial.

3

A systematic review of noninferiority margins in oncology clinical trials.

Hashim M, Vincken T, Kroi F, Gebregergish S, Spencer M, Wang J, Kampfenkel T, Lam A, He J. Hashim M, et al. Among authors: lam a. J Comp Eff Res. 2021 Apr;10(6):443-455. doi: 10.2217/cer-2020-0200. Epub 2021 Mar 17. J Comp Eff Res. 2021. PMID: 33728935 Free article.

4

Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, van Beekhuizen S, Yuan Z, Mendes J, Lam A, He J, Ammann E, Kumar S. Facon T, et al. Among authors: lam a. Adv Ther. 2022 May;39(5):1976-1992. doi: 10.1007/s12325-022-02083-8. Epub 2022 Mar 5. Adv Ther. 2022. PMID: 35246820 Free PMC article.

5

Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, van Beekhuizen S, Yuan Z, Mendes J, Lam A, He J, Ammann E, Kumar S. Facon T, et al. Among authors: lam a. Adv Ther. 2022 Aug;39(8):3868-3869. doi: 10.1007/s12325-022-02211-4. Adv Ther. 2022. PMID: 35764866 Free PMC article. No abstract available.

6

Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.

Dispenzieri A, Zonder J, Hoffman J, Wong SW, Liedtke M, Abonour R, D'Souza A, Lee C, Cote S, Potluri R, Ammann E, Tran N, Lam A, Nair S. Dispenzieri A, et al. Among authors: lam a. Amyloid. 2023 Jun;30(2):161-168. doi: 10.1080/13506129.2022.2137400. Epub 2022 Oct 25. Amyloid. 2023. PMID: 36282014

7

Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis.

Kastritis E, Misra A, Gurskyte L, Kroi F, Verhoek A, Vermeulen J, Ammann E, Lam A, Cote S, Wechalekar AD. Kastritis E, et al. Among authors: lam a. Hematology. 2023 Dec;28(1):2157581. doi: 10.1080/16078454.2022.2157581. Hematology. 2023. PMID: 36607151

8

Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma.

Fonseca R, Facon T, Hashim M, Nair S, He J, Ammann E, Lam A, Wildgust M, Kumar S. Fonseca R, et al. Among authors: lam a. Oncologist. 2023 May 8;28(5):e263-e269. doi: 10.1093/oncolo/oyad053. Oncologist. 2023. PMID: 37002943 Free PMC article.

9

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.

Durie BGM, Kumar SK, Ammann EM, Fu AZ, Kaila S, Lam A, Usmani SZ, Facon T. Durie BGM, et al. Among authors: lam a. Adv Ther. 2024 May;41(5):1923-1937. doi: 10.1007/s12325-024-02807-y. Epub 2024 Mar 18. Adv Ther. 2024. PMID: 38494542 Free PMC article.

10

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.

Moreau P, Hebraud B, Facon T, Leleu X, Hulin C, Hashim M, Hu Y, Caillot D, Benboubker L, Zweegman S, Merz M, Weisel K, Salwender H, Mai EK, Goldschmidt H, Bertsch U, Vanquickelberghe V, Kampfenkel T, Boer C, Krotneva S, Proskorovsky I, He J, Lam A, Lee C, Cote S, Sonneveld P. Moreau P, et al. Among authors: lam a. Immunotherapy. 2021 Feb;13(2):143-154. doi: 10.2217/imt-2020-0266. Epub 2020 Nov 24. Immunotherapy. 2021. PMID: 33228440

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,186 results

Search Page